Preventative IP for preventative pharma healthcare

The shift towards preventative pharmaceuticals could open new, and highly valuable, markets but it must be strengthened by patent rights, says Sam Andrews, senior paralegal at Powell Gilbert.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Biotech

Guardant loses second patent challenge to TwinStrand amid $245m damages fallout

16 October 2026 All 30 claims of a key DNA sequencing patent have been upheld for a second time, marking another setback in a long-running dispute that has already left Guardant facing a $245 million bill.

Biotech

Scientist and Chinese biotech targeted by Beam in secrets suit

29 September 2026 The gene-editing company has accused a former employee of secretly co-founding a Chinese biotech while still at the company, in a trade secrets lawsuit involving rival base-editing therapies and disputed patent filings.

Biotech

Oxford Nanopore scores urgent injunction at UPC in DNA sequencing fight

21 September 2026 Judges agreed with the Oxford University spin-out that MGI Tech was likely to infringe Oxford’s patent, and banned sales of certain Cyclone devices to preserve the one-player-market status quo.

More features

Fed Circ refuses to rehear Insulet’s $59.4m trade secret loss

Align Technology notches another win in escalating clear aligner feud

Guardant loses second patent challenge to TwinStrand amid $245m damages fallout

Haynes Boone expands in California with new office

Accord’s generic hopes dashed in cyanide antidote ruling

Novo’s semaglutide protection weakens after European ruling

Boston Scientific expands dispute with J&J unit over cardiac-access technology

AIPPI World Congress: ‘Diversity need not be an obstacle to unity’

Preventative IP for preventative pharma healthcare

More on this story

Editor's picks

Editor's picks

More features